Recent research from Mauna Kea Technologies, published in Techniques and Innovations in Gastrointestinal Endoscopy, has shown that use of the multidisciplinary probe and needle-based confocal laser endomicroscopy system Cellvizio can improve diagnoses for dysplasia and esophageal cancer when compared to standard biopsies, the current standard of care.
The meta-analysis included nine studies, and involved a total of 688 patients and also 1,299 lesions according to Becker’s. The analysis studies the benefits of probe-based confocal laser endomicroscopy in comparison with randomized four-quadrant biopsies in order study patients with Barret’s esophagus for dysplasia and early adenocarcinoma detection.
“The study demonstrates that the addition of Cellvizio as an adjunct to guide biopsies provides a significantly higher diagnostic yield for dysplasia and cancer and reduces sampling error compared to random four-quadrant biopsies alone, the (current) standard of care,” the study reads.
Portions of the findings were presented at the ENDO 2022 World Congress of GI Endoscopy in May. This included a study analyzing the differences in usage of GI services. Study authors focused on eight items and services for patients treated using Cellvizio rather than the standard service of care. Results showed that these patients “had 1.04 fewer endoscopies and anesthesia services, 7.49 fewer biopsy bottles, 1.30 fewer ablations and 1.46 fewer brush cytology services,” Becker’s report states.
Nicolas Bouvier, Interim CEO of Mauna Kea Technologies, added that the addition of Cellvizio can play a vital role in the increase in esophageal cancer cases. Bouvier said that he believes the meta-analysis shows that easily accessible tools, such as Cellvizio, can assist physicians in improving screening and detection rates among patients.
Read the full press release from Mauna Key Technologies by clicking here.
